On May 28, 2026 HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, reported that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HanchorBio is focused on developing differentiated immunotherapies targeting large unmet needs in oncology and autoimmune diseases. The Company’s core technology is its proprietary FBDB platform, which integrates multiple immune-modulating mechanisms into a single molecule and supports the development of multi-target, multifunctional biologic therapies.

Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, said platform technology is an important foundation for building long-term biotechnology value. By supporting the generation of multiple research and development assets over time, platform capabilities may help diversify risks associated with single-asset drug development while strengthening the long-term potential of the Company’s pipeline.

HanchorBio has built a pipeline of clinical and preclinical candidates, including HCB101, HCB301, HCB303, and HCB206. The Company’s lead program, HCB101, is a CD47-targeting anti-cancer drug candidate designed through precision protein engineering to block tumor immune-evasion signals and restore macrophage-mediated tumor phagocytosis. HCB101 is currently being advanced in Phase 2a clinical development in combination with ramucirumab and paclitaxel for gastric cancer, while also being evaluated in additional indications, including head and neck cancer, colorectal cancer, and triple-negative breast cancer.

HCB301, a trifunctional fusion protein designed to address three key tumor immune-escape mechanisms, has entered Phase 1 clinical trials in the United States, mainland China, and Taiwan. HCB303 is a next-generation multi-target immunotherapy candidate currently under clinical development planning, while HCB206, the Company’s dual-mechanism autoimmune disease program, is viewed as an important potential driver of future pipeline value.

Dr. Liu noted that, in biotechnology licensing and partnership discussions, early clinical data supported by proof-of-concept findings are often a key factor in attracting global pharmaceutical partners. Such data may provide initial evidence of safety, clinical activity, and potential differentiation in patients.

HCB101 has shown encouraging early clinical activity in ongoing multinational Phase 1b/2a studies. In a mid-dose cohort evaluating HCB101 in combination with standard therapy for second-line gastric cancer, the regimen demonstrated an objective response rate (ORR) of 80%, with favorable safety and tumor reduction observations. Preliminary data from gastric cancer and first-line triple-negative breast cancer cohorts have also shown encouraging response and disease control signals. If subsequent Phase 2a proof-of-concept data across multiple indications remain supportive, the Company believes HCB101 may further positioned for global partnering discussions.

HanchorBio is pursuing a multi-indication clinical development strategy for HCB101, designed to support flexible business development opportunities, including licensing, co-development, and potential strategic transactions. Following its licensing agreement last year with Henlius for the development and commercialization rights to HCB101 in mainland China and certain territories, valued at up to US$202 million, HanchorBio has continued to advance discussions with multiple global pharmaceutical companies. The Company is currently engaged in ongoing partnering discussions for global and regional rights to HCB101 outside previously licensed territories.

(Press release, Hanchor Bio, MAY 28, 2026, View Source [SID1234666167])

On May 28, 2026 Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) reported that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world’s most influential scientific meeting in the lung cancer field, taking place September 12–15, where Leads Biolabs will present breakthrough efficacy data based on an expanded patient cohort compared to the previously reported 18-patient dataset.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Previously reported early-stage NSCLC data showed that Opamtistomig combined with chemotherapy achieved a compelling objective response rate (ORR). With extended follow-up, deepening tumor responses and durable tumor shrinkage were observed across multiple subgroups, including immunotherapy-pretreated non-squamous NSCLC, first-line non-squamous NSCLC, and first-line squamous NSCLC.

At WCLC 2026, the Company will present updated data demonstrating high response rates and continuously deepening tumor shrinkage of Opamtistomig in an expanded patient population, along with a safety profile consistent with previous findings. These results further validate the safety breakthrough enabled by conditional 4-1BB activation via the X-body platform and highlight Opamtistomig’s differentiated clinical advantages in first-line NSCLC.

Opamtistomig’s potential as an IO 2.0 pan-tumor backbone therapy is being validated in three key dimensions—broad antitumor activity, long-term survival benefit trends, and a safety profile comparable to PD-(L)1 inhibitors: its clinical development spans 13 solid tumor indications, demonstrating first- or best-in-class potential in multiple tumor types, including NSCLC, extrapulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), and biliary tract cancer (BTC); clear survival benefit trends have been observed in multiple indications, with potential to translate into long-term efficacy benefits with continued follow-up; and with over 600 patients enrolled, Opamtistomig demonstrated a favorable safety profile as monotherapy and in combination with chemotherapy, with no dose-limiting toxicities observed and the maximum tolerated dose not reached at doses up to 25.0 mg/kg.

Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "The selection for an oral presentation at WCLC represents strong recognition from the international academic community of Opamtistomig’s innovative mechanism and clinical value, and further validates its breakthrough therapeutic potential in first-line NSCLC. As we accumulate data from larger patient cohorts and longer follow-up, we continue to observe significant trends toward deeper and more durable responses across broader patient populations. We look forward to sharing these important findings with global experts at WCLC and continuing to advance Opamtistomig toward becoming a new backbone of cancer immunotherapy worldwide."

About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs’ proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. To date, Opamtistomig has demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across four indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), and extrapulmonary neuroendocrine carcinoma (EP-NEC).

As the first 4-1BB–targeting bispecific antibody globally to advance to a single-arm pivotal trial as monotherapy, Opamtistomig has been evaluated in 13 solid tumor indications in China, including 1 pivotal registration trial and 8 proof-of-concept studies. These cover EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), malignant melanoma, and other areas with high unmet medical needs.

Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically "cold" tumors. Recognizing its clinical potential, Opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinoma in November 2024. Additionally, in January 2026, Opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission for the treatment of EP-NEC, further underscoring its potential to address unmet medical needs in this patient population.

(Press release, Nanjing Leads Biolabs, MAY 28, 2026, View Source [SID1234666166])

On May 28, 2026 PeproMene Bio, Inc. reported that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association (EHA) (Free EHA Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This presentation will highlight results from the completed dose-escalation portion of the study in relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients whose cancer has progressed following standard CD19-directed CAR T-cell therapy (NCT05370430).

Among the nine patients treated in this phase, PMB-CT01 demonstrated a promising safety profile with no dose-limiting toxicities, no grade >1 cytokine release syndrome (CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR). At the last data cutoff, no relapses had occurred and all responses remained ongoing, with the longest response exceeding 3 years. Responding patients also achieved minimal residual disease (MRD)-negative status, indicating deep remissions with no detectable residual cancer cells.

Building on these results, the trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL). Importantly, the first patient treated in this expansion phase – a patient with transformed FL (tFL) who had progressed following CD19 CAR T therapy – achieved a CR at their first disease assessment. tFL is an aggressive form of lymphoma with limited established treatment options.

"When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical need, with very limited treatment options remaining," said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. "These durable CRs clinically validate BAFF-R as a novel target, while the favorable safety profile observed to date may support future use in outpatient community oncology settings and further exploration in refractory autoimmune diseases."

Presentation Details

Abstract Title: Durable responses and favorable safety of BAFF-R CAR T-cells (PMB-CT01) in patients with relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Abstract: EHA (Free EHA Whitepaper)-1611 S287

Date/Time: June 14, 11:00 AM – 12:15 AM CEST

Presenter: Larry W. Kwak, M.D., Ph.D.

About PMB-CT01

PMB-CT01 is a first-in-class BAFF-R-targeted autologous CAR T-cell therapy being evaluated in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape.

(Press release, PeproMene Bio, MAY 28, 2026, View Source [SID1234666165])

On May 28, 2026 Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) reported that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, which is being held from May 29-June 2, 2026, in Chicago, IL. The abstract titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors" has been published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track and can be viewed on the ASCO (Free ASCO Whitepaper) website (View Source).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract reports the findings from an ongoing first-in-human study of LNP8701 in patients with solid tumors. LNP8701 is an orally administered, investigational SOS1 (Son of Sevenless1) inhibitor, designed to block SOS1-mediated RAS activation, thereby limiting oncogenic signaling that promotes tumor growth. Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles (i.e., 1 year) and one patient completed 14 cycles with stable disease.

Vinita Gupta, CEO, Lupin, said, "The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes."

Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.

Details of the Abstract:

Abstract Number: e15162
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162)
DOI: 10.1200/JCO.2026.44.16_suppl.e15162
Clinical Trial Registration Number: CTRI/2024/08/072373
Abstract link: View Source

(Press release, Lupin, MAY 28, 2026, View Source [SID1234666164])

On May 28, 2026 Bold Therapeutics, a clinical-stage biopharmaceutical company founded to develop and commercialize novel metallotherapeutics, reported data to support the neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of patients with advanced gastrointestinal cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This data is presented in an abstract as part of the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago from May 29th to June 2nd.

Abstract title: Neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of advanced gastrointestinal cancers.
Authors: Grainne M. O’Kane, Elena Elimova, Jennifer L. Spratlin, Rachel A. Goodwin, Elaine McWhirter, Petr Kavan, Joel R. Hecht, Dae Won Kim, Do-Youn Oh, Sun Young Rha, Seung Tae Kim, Moon Ki Choi, Dong-Hoe Koo, Mark Bazett, Malcolm Snow, Michelle A. Jones, Jim Pankovich

Abstract #: e15029
View Source

Summary

Results: 109 participants with advanced gastrointestinal cancer were evaluated in the study and all but one had prior chemotherapy in the advanced setting. 95% were previously treated with oxaliplatin (65%) or cisplatin (30%). 45 patients (41%) had prior neuropathy. On study, 24 patients (22%) experienced at least one oxaliplatin-induced peripheral neuropathy (OIPN) adverse event. Lower OIPN incidence was observed across all cohorts relative to benchmarks: mCRC (14% vs. 53%), BTC (32% vs. 68%), GC (19% vs. 63%), and pancreatic cancer (29% vs. 38%). Only 9 patients (8.2%) discontinued oxaliplatin, with only 2 attributed to OIPN. Of 69 dose reductions, 16 (23%) were due to OIPN. Patients at the highest BOLD-100 dose level (625 mg/m2) had the lowest OIPN incidence.

Conclusions: Analysis of safety and dosing data from this study suggests a potential neuroprotective effect of BOLD-100 against oxaliplatin-induced peripheral neuropathy.

Bold Therapeutics is currently advancing BOLD-100 through a global Phase 2 randomized controlled trial across sites in Canada, European Union, and South Korea. This trial is investigating BOLD-100’s anticancer efficacy, but also includes important quality of life questionnaires focused on its neuroprotective potential. Please visit ClinicalTrials.gov for more information (NCT04421820).

(Press release, Bold Therapeutics, MAY 28, 2026, View Source [SID1234666163])